While most biotechs struggle amid a prolonged funding winter, one group is doing just fine. We are not talking about artificial intelligence. Several start-ups working on nucleic acid-based therapies – a sprawling category that includes several flavors of RNA, anti-sense oligonucleotides (ASOs), aptamers (short single stranded oligonucleotides) and gene-edited cell and gene therapies – are raising bigger-than-average rounds. Four of the top five private financings in 2023 have been companies working on RNA, gene editing or manufacturing. ReNAgade Therapeutics and Orbital Therapeutics each pulled in over $250m; this year’s biggest round yet brought ElevateBio, with its suite of gene- and cell-editing tools, more than $400m.
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
More from Innovation
• By
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.
• By
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.
• By
In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based AI agent to streamline clinical trial processes.
More from In Vivo
• By
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.
• By
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
• By
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.